FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216673161> ?p ?o ?g. }

• W3216673161 endingPage "8875" @default.
• W3216673161 startingPage "8866" @default.
• W3216673161 abstract "Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose-adjusted (DA) EPOCH-R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has become widely endorsed as first-line therapy for newly-diagnosed PMBCL, the optimal treatment for this disease and the role of radiotherapy (RT) remains unclear. DA-EPOCH-R provides good clinical outcomes, albeit is associated with short- and long-term toxicity. To address this issue, the current retrospective bi-icenter analysis compared efficacy and toxicity of DA-EPOCH-R and a less toxic R-CHOP/R-ICE regimen used for the treatment of newly-diagnosed PMBCL.The study included all patients with a histologically confirmed PMBCL diagnosis treated with DA-EPOCH-R or R-CHOP/R-ICE between 01/2013-12/2020 at two tertiary medical centers. Patient demographic and clinical data were derived from institutional electronic medical records. The analysis included 56 patients: 31 received DA-EPOCH-R and 25 - R-CHOP/R-ICE.At a median follow-up of 1.9 years (IQR 3.1 years), similar progression-free survival (2.1 versus 2.4 years; p = 0.7667), overall survival (2.5 versus 2.7 years; p = 0.8047) and complete response (80%) were observed in both groups. However, DA-EPOCH-R was associated with significantly longer hospitalization required for its administration (p < 0.001) and a trend for higher frequency of infections, stomatitis, thrombotic complications and febrile neutropenia-related hospitalizations.DA-EPOCH-R and R-CHOP/R-ICE provide similarly encouraging outcomes in newly-diagnosed PMBCL patients. R-CHOP/R-ICE is associated with lower toxicity and significantly reduced hospitalization. Our findings suggest that this regimen may be considered as an alternative to DA-EPOCH-R in this patient population." @default.
• W3216673161 created "2021-12-06" @default.
• W3216673161 creator A5001981855 @default.
• W3216673161 creator A5012003196 @default.
• W3216673161 creator A5023585815 @default.
• W3216673161 creator A5024868141 @default.
• W3216673161 creator A5032967792 @default.
• W3216673161 creator A5070181461 @default.
• W3216673161 date "2021-11-24" @default.
• W3216673161 modified "2023-09-30" @default.
• W3216673161 title "Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study" @default.
• W3216673161 cites W1565770295 @default.
• W3216673161 cites W2001196047 @default.
• W3216673161 cites W2022551460 @default.
• W3216673161 cites W2030849248 @default.
• W3216673161 cites W2098320431 @default.
• W3216673161 cites W2111500154 @default.
• W3216673161 cites W2130929003 @default.
• W3216673161 cites W2138265225 @default.
• W3216673161 cites W2143118351 @default.
• W3216673161 cites W2163990748 @default.
• W3216673161 cites W2273432951 @default.
• W3216673161 cites W2310716991 @default.
• W3216673161 cites W2318277080 @default.
• W3216673161 cites W2555934645 @default.
• W3216673161 cites W2617274350 @default.
• W3216673161 cites W2765486607 @default.
• W3216673161 cites W2780959200 @default.
• W3216673161 cites W2801174360 @default.
• W3216673161 cites W2910591463 @default.
• W3216673161 cites W2911594484 @default.
• W3216673161 cites W2950253253 @default.
• W3216673161 cites W2953511027 @default.
• W3216673161 cites W2970198725 @default.
• W3216673161 cites W2979889594 @default.
• W3216673161 cites W3022588648 @default.
• W3216673161 cites W3032539218 @default.
• W3216673161 cites W3039967857 @default.
• W3216673161 cites W3126620286 @default.
• W3216673161 cites W3135826314 @default.
• W3216673161 cites W3216673161 @default.
• W3216673161 doi "https://doi.org/10.1002/cam4.4387" @default.
• W3216673161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34816617" @default.
• W3216673161 hasPublicationYear "2021" @default.
• W3216673161 type Work @default.
• W3216673161 sameAs 3216673161 @default.
• W3216673161 citedByCount "4" @default.
• W3216673161 countsByYear W32166731612021 @default.
• W3216673161 countsByYear W32166731612022 @default.
• W3216673161 countsByYear W32166731612023 @default.
• W3216673161 crossrefType "journal-article" @default.
• W3216673161 hasAuthorship W3216673161A5001981855 @default.
• W3216673161 hasAuthorship W3216673161A5012003196 @default.
• W3216673161 hasAuthorship W3216673161A5023585815 @default.
• W3216673161 hasAuthorship W3216673161A5024868141 @default.
• W3216673161 hasAuthorship W3216673161A5032967792 @default.
• W3216673161 hasAuthorship W3216673161A5070181461 @default.
• W3216673161 hasBestOaLocation W32166731611 @default.
• W3216673161 hasConcept C121332964 @default.
• W3216673161 hasConcept C126322002 @default.
• W3216673161 hasConcept C1276947 @default.
• W3216673161 hasConcept C141071460 @default.
• W3216673161 hasConcept C143998085 @default.
• W3216673161 hasConcept C150846664 @default.
• W3216673161 hasConcept C167135981 @default.
• W3216673161 hasConcept C2776694085 @default.
• W3216673161 hasConcept C2776755627 @default.
• W3216673161 hasConcept C2777063308 @default.
• W3216673161 hasConcept C2778720950 @default.
• W3216673161 hasConcept C2778850193 @default.
• W3216673161 hasConcept C2779338263 @default.
• W3216673161 hasConcept C2779429289 @default.
• W3216673161 hasConcept C2780073493 @default.
• W3216673161 hasConcept C2780317896 @default.
• W3216673161 hasConcept C2780653079 @default.
• W3216673161 hasConcept C2781413609 @default.
• W3216673161 hasConcept C71924100 @default.
• W3216673161 hasConceptScore W3216673161C121332964 @default.
• W3216673161 hasConceptScore W3216673161C126322002 @default.
• W3216673161 hasConceptScore W3216673161C1276947 @default.
• W3216673161 hasConceptScore W3216673161C141071460 @default.
• W3216673161 hasConceptScore W3216673161C143998085 @default.
• W3216673161 hasConceptScore W3216673161C150846664 @default.
• W3216673161 hasConceptScore W3216673161C167135981 @default.
• W3216673161 hasConceptScore W3216673161C2776694085 @default.
• W3216673161 hasConceptScore W3216673161C2776755627 @default.
• W3216673161 hasConceptScore W3216673161C2777063308 @default.
• W3216673161 hasConceptScore W3216673161C2778720950 @default.
• W3216673161 hasConceptScore W3216673161C2778850193 @default.
• W3216673161 hasConceptScore W3216673161C2779338263 @default.
• W3216673161 hasConceptScore W3216673161C2779429289 @default.
• W3216673161 hasConceptScore W3216673161C2780073493 @default.
• W3216673161 hasConceptScore W3216673161C2780317896 @default.
• W3216673161 hasConceptScore W3216673161C2780653079 @default.
• W3216673161 hasConceptScore W3216673161C2781413609 @default.
• W3216673161 hasConceptScore W3216673161C71924100 @default.
• W3216673161 hasIssue "24" @default.
• W3216673161 hasLocation W32166731611 @default.

• next